Please login to the form below

Not currently logged in
Email:
Password:

GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

She will become CEO designate at the HIV-focused firm in January

ViiV Deborah WaterhouseGlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March.

Limet has served as ViiV's CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012.

He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy.

“We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business.”

Waterhouse, who is currently senior VP of primary care within GSK's US pharmaceuticals business will take up a CEO designate role at ViiV in January, when she will be replaced by the company's VP of US primary care sales Cheryl MacDiarmid.

23rd December 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics